Impact of COVID-19 on Obstructive Sleep Apnea

The coronavirus disease 2019 (COVID-19) pandemic has caused major psychological distress, mental health problems, sleep disturbances, anxiety, and depression. Among them, obstructive sleep apnea (OSA) is known as a comorbidity of diabetes, cardiovascular disease, asthma, obesity, high blood pressure, and chronic obstructive pulmonary disease, and these are poor prognostic factors for COVID-19 morbidity. Therefore, it is important to properly diagnose and treat sleep apnea during the COVID-19 pandemic. Due to the pandemic of COVID-19, in-lab sleep studies such as polysomnography (PSG) tend to slightly decrease, and alternative methods such as home sleep apnea tests (HSAT) and telemedicine tend to emerge relatively. In the post-COVID-19 era, HSAT with a technically adequate device and telemedicine may become an important modality for the diagnosis and treatment of OSA. In addition, the protection of PSG technicians and the disinfection of equipment and the environment of in-lab sleep studies are emphasized. If COVID-19 is ruled out, the use of positive airway pressure devices for therapeutic purposes is not restricted, but efforts should be made to minimize the risk of aerosol generation. Infection and quality control in PSG are important and inevitable issues, and regulation within each institution will be required during and after the COVID-19 pandemic.